Literature DB >> 12532382

Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Yuh-Fun Maa1, Lu Zhao, Lendon G Payne, Dexiang Chen.   

Abstract

Studies were performed to elucidate the mechanism of alum gel coagulation upon freezing and drying and its relationship to vaccine potency loss and to develop a novel freeze-drying process for the production of stable alum-adjuvanted vaccine formulations suitable for conventional needle injection and epidermal powder immunization (EPI). The alum hydroxide-adjuvanted hepatitis-B surface antigen (Alum-HBsAg) and the alum phosphate-adjuvanted diphtheria and tetanus toxoids (Alum-DT) were dehydrated by freeze drying (FD), spray drying (SD), air drying (AD), or spray freeze drying (SFD). After drying by FD, SD, or AD, alum gels coagulated when examined by optical microscopy and particle size analysis. In addition, desorption of antigen molecules from the coagulated when examined by optical microscopy and particle size analysis. In addition, desorption of antigen molecules from the coagulated alum gel upon reconstitution appeared to be difficult, as indicated by attenuated band intensity on SDS-PAGE. In contrast, SFD alum gels turned a homogenous suspension upon reconstitution, suggesting minimal alum coagulation. In the mouse model, the in vivo immunogenicity of SFD Alum-HBsAg was preserved, whereas the FD Alum-HBsAg suffered significant immunogenicity loss. Grinding of coagulated FD Alum-HBsAg into smaller particles could partially recover the immunogenicity. In a guinea pig study using EPI, the SD Alum-DT formulation was not immunogenic, but the SFD Alum-DT formulations had a vaccine potency comparable to that of the untreated DT administered by I.M. injection. Overall, the relationship of coagulation of alum gel upon reconstitution and the loss of vaccine potency was established in this study. Alum gels became highly coagulated after dehydration by spray drying and traditional freeze-drying processes. However, freezing rate played a critical role in preserving the adjuvant effect of alum and fast freezing decreased the tendency of alum coagulation. Spraying the alum gel into liquid nitrogen represents the fastest freezing rate achievable and resulted in no discernible alum coagulation. Therefore, SFD presents a novel and effective drying process for alum-adjuvanted vaccine formulations and is particularly valuable for dry powder applications such as EPI. Copyright 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 92:319-332, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532382     DOI: 10.1002/jps.10294

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application.

Authors:  Yuh-Fun Maa; Mahmoud Ameri; Robert Rigney; Lendon G Payne; Dexiang Chen
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

2.  Formation of stable submicron protein particles by thin film freezing.

Authors:  Joshua D Engstrom; Edwina S Lai; Baltej S Ludher; Bo Chen; Thomas E Milner; Robert O Williams; G Barrie Kitto; Keith P Johnston
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

3.  Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.

Authors:  M Autumn Smiley; Daniel C Sanford; Cheryl A Triplett; Daniel Callahan; Vladimir Frolov; Jee Look; Christian Ruiz; Joshua J Reece; Aaron Miles; Ericka Ruiz; Boris Ionin; Jeffry D Shearer; Vladimir Savransky
Journal:  Vaccine       Date:  2019-09-14       Impact factor: 3.641

4.  A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.

Authors:  Xinran Li; Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2015-02-28       Impact factor: 9.776

5.  Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors:  Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2013-04-10       Impact factor: 5.571

6.  Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.

Authors:  Carly Fleagle Chisholm; Taek Jin Kang; Miao Dong; Kasey Lewis; Madhuri Namekar; Axel T Lehrer; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2019-01-28       Impact factor: 5.571

7.  Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

Authors:  Holly J Corbett; Germain J P Fernando; Xianfeng Chen; Ian H Frazer; Mark A F Kendall
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

8.  Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.

Authors:  Yuh-Fun Maa; Cassandra Shu; Mahmoud Ameri; Cindy Zuleger; Jenny Che; Jorge E Osorio; Lendon G Payne; Dexiang Chen
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 9.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

10.  Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine.

Authors:  Amber L Clausi; Andrea Morin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.